Quarterly report pursuant to Section 13 or 15(d)

Segment Information (Schedule of Segment Information) (Details)

v3.24.1.1.u2
Segment Information (Schedule of Segment Information) (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Segment Reporting Information [Line Items]    
Net Revenue $ 13,030 $ 12,429
Cost of goods - product revenue (6,816) (6,449)
Research and development (24,839) (39,506)
Selling, general and administrative (17,941) (25,341)
Other expense (2,457) 3,722
Income tax expense 0 0
Net loss (39,023) (55,145)
Dermatology Products Sales    
Segment Reporting Information [Line Items]    
Net Revenue 13,030 12,213
Cost of goods - product revenue (6,816) (6,449)
Research and development (7,884) (2,033)
Selling, general and administrative (8,420) (13,291)
Other expense (352) (575)
Net loss (10,442) (10,135)
Pharmaceutical and Biotechnology Product Development    
Segment Reporting Information [Line Items]    
Net Revenue   216
Research and development (16,955) (37,473)
Selling, general and administrative (9,521) (12,050)
Other expense (2,105) 4,297
Net loss $ (28,581) $ (45,010)